Insights
Insights From Our Experts
Articles
Booming but Constrained: Digital Therapeutics for Mental Health in APAC
Digital therapeutics (DTx) are a fast-emerging class of therapies that use software to treat disease, both as standalone treatments and for treatment optimization. Applications range from improving patient adherence to supporting physicians in managing patients remotely.…
New Medicines, New Access, New Frontiers
How psychedelics, cell therapies and other innovations are driving regulatory reform and new patient access Science is improving exponentially. What’s now possible, through new medicines, and entirely new categories of medicine, could only be dreamt of…
Is Your Digital Communication Strategy Up to Par?
In today’s competitive global market, pharmaceutical companies cannot afford to waste time or resources on strategies that do not fit patient needs or generate scripts. Interconnectivity between all stakeholders and a 360° view of everything that…
EVERSANA’s Integrated Operations, Data-Driven Solutions and Digital Expertise Solve Key Challenges in Market Access and Field Deployment
Pharmaceutical manufacturers relying on the standard model for executing market access and field deployment strategies utilize resources inefficiently and redundantly. By integrating actions across operations, manufacturers can right size company resources, ensure affordability and increase speed…
Demystifying Data and Analytics – How to Advance Clinical and Business Objectives
The need to develop a strong, comprehensive data-analytics strategy to support pharma and healthcare initiatives cannot be stated strongly enough. Data is unbiased; it can validate hypotheses or provide direction. But the primary goal is to…
Pharmaceutical Distribution – Right-Sizing the Channel Strategy for Maximum Impact
In recent years, there has been increasing appetite among manufacturers — and growing capabilities among specialized channel-distribution service providers — to shorten the value chain. When drug manufacturers reflexively commit to a distribution model that is…
FDA Moves Cybersecurity Into the Product Life Cycle
Due to rising cyber-attacks and the potential to cause harm to patients, medical facilities and hospitals, the U.S. Food and Drug Administration (FDA) has recently increased scrutiny of cyber controls in FDA premarket submissions of medical…
EVERSANA Featured in NIH Study Detailing the Cost of Treating Rare Disease
“The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems” EVERSANA™ was the only data and analytic organization invited by a consortium of provider organizations and the NIH to…
Reigniting Revenue for Established Brands
Established brands do not require significant proactive investment or attention from commercial teams and generate revenue for biopharma companies to reinvest and improve healthcare value for patients, providers and payers. Established brands have seen a decrease…
Reframing the Challenges of Access and ROI
Pharma companies today are being judged not just on their profitability for shareholders, but also on the extent to which their products are accessible to patients. Today’s Environmental, Social and Governance (ESG) investors want to see…